Circio Holding ASA

The biopharmaceutical industry finds itself at a critical juncture in early 2025, confronting unprecedented levels of geopolitical uncertainty and market disruption. The sector faces fundamental chall

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

The reason Erik Wiklund can so clearly recall the evolution of the science of circular RNA is that he was there from the outset. “In the late 2000s, during my PhD work in molecular biology, Thomas Han

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Seeking To Replicate Vraylar Success, A